Ciprofloxacin and ursodeoxycholic acid tab Ofloxacin and Ornidazole
Reading Document
Medical Text Search
Ciprofloxacin ursodeoxycholic acid combination tablet uses dosage
Medical Text Search
Ofloxacin Ornidazole combination tablet uses dosage indications
GradeResponse
GradeResponse
The database retrieval was limited, so I'll provide a comprehensive answer from established pharmacological knowledge.
Drug Combination Profiles
1. Ciprofloxacin + Ursodeoxycholic Acid (UDCA) Tablet
Drug Components
| Component | Class | Mechanism |
|---|---|---|
| Ciprofloxacin | Fluoroquinolone antibiotic | Inhibits bacterial DNA gyrase (topoisomerase II & IV), bactericidal |
| Ursodeoxycholic Acid (UDCA) | Bile acid | Reduces biliary cholesterol saturation, anti-inflammatory, hepatoprotective |
Rationale for Combination
This combination targets biliary tract infections where both antimicrobial therapy and bile flow modification are needed simultaneously — particularly cholangitis, cholecystitis, and biliary sepsis.
- Ciprofloxacin achieves excellent biliary concentration and covers gram-negative biliary pathogens
- UDCA improves bile rheology, reduces cholestasis, and has direct cytoprotective effects on hepatocytes and cholangiocytes
Indications
- Cholangitis (acute bacterial cholangitis)
- Cholecystitis with biliary stasis
- Primary biliary cholangitis (PBC) with superimposed infection
- Biliary dyskinesia with bacterial overgrowth
- Post-cholecystectomy syndrome with infection
Dosage (Typical)
| Parameter | Details |
|---|---|
| Ciprofloxacin component | 250–500 mg |
| UDCA component | 150–300 mg |
| Frequency | Twice daily (BD) |
| Duration | 5–14 days depending on indication |
| Route | Oral |
Key Precautions
- Avoid in renal impairment (adjust ciprofloxacin dose)
- Ciprofloxacin interacts with antacids, dairy products (chelation — reduce absorption; separate by 2 hrs)
- Tendinopathy/tendon rupture risk with ciprofloxacin (especially in elderly, corticosteroid users)
- QT prolongation risk — avoid with other QT-prolonging agents
- UDCA contraindicated in acute cholecystitis flare with complete biliary obstruction
- Avoid fluoroquinolones in children and pregnant women
2. Ofloxacin + Ornidazole Tablet
Drug Components
| Component | Class | Mechanism |
|---|---|---|
| Ofloxacin | Fluoroquinolone antibiotic | Inhibits DNA gyrase & topoisomerase IV; bactericidal against gram-negative and gram-positive organisms |
| Ornidazole | 5-Nitroimidazole (nitroimidazole derivative) | Forms cytotoxic free radicals that damage microbial DNA; active against anaerobes and protozoa |
Rationale for Combination
This is a broad-spectrum antimicrobial combination — ofloxacin covers aerobic bacteria while ornidazole covers anaerobes and protozoa (Giardia, Entamoeba, Trichomonas). Together they address mixed aerobic-anaerobic infections, which are common in GI and pelvic pathology.
Indications
- Acute infectious diarrhea / gastroenteritis (mixed bacterial + protozoal)
- Giardiasis, Amoebiasis (intestinal and hepatic)
- Pelvic inflammatory disease (PID)
- Bacterial vaginosis and Trichomoniasis
- Intra-abdominal infections (peritonitis, diverticulitis)
- Surgical prophylaxis (GI/colorectal surgery)
- H. pylori eradication (as part of a regimen)
Dosage (Typical)
| Parameter | Details |
|---|---|
| Ofloxacin component | 200 mg |
| Ornidazole component | 500 mg |
| Frequency | Twice daily (BD) — after meals |
| Duration | 3–7 days (diarrhea/GI); 5–10 days (PID, amoebiasis) |
| Route | Oral |
Common brand example: Ornof, Oflagyl-O, Zanocin-OZ
Key Precautions
- Avoid alcohol — ornidazole causes disulfiram-like reaction (flushing, vomiting, tachycardia)
- Ornidazole is safer than metronidazole in terms of neurological side effects, though prolonged use can still cause peripheral neuropathy
- Ofloxacin: risk of tendinopathy, photosensitivity, QT prolongation
- Avoid in epilepsy — both drugs can lower seizure threshold
- Pregnancy: avoid in first trimester; use with caution in later trimesters
- Pediatric use: generally avoided in children < 18 years due to fluoroquinolone risk to developing cartilage
Quick Comparison
| Feature | Cipro + UDCA | Ofloxacin + Ornidazole |
|---|---|---|
| Primary target | Biliary tract infections | GI, pelvic, protozoal infections |
| Antibiotic | Ciprofloxacin | Ofloxacin |
| Second agent | Hepatoprotective / bile acid | Antiprotozoal / anti-anaerobic |
| Key use | Cholangitis, cholestasis | Diarrhea, PID, amoebiasis |
| Alcohol interaction | No (ciprofloxacin) | Yes (ornidazole — avoid alcohol) |
| Spectrum | Gram-negatives + biliary | Broad aerobic + anaerobic + protozoal |
Note: Both combinations contain fluoroquinolones. Use judiciously to minimize antibiotic resistance. Always prescribe based on clinical indication, culture sensitivity (where available), and local resistance patterns.
Ciprofloxacin and ursodeoxycholic acid tab Ofloxacin and Ornidazole Tab zerodol sp tab crina ncr tab itraconazole and tab levocitrizine may cause contraindications in pregnancy
Medical Text Search
Ciprofloxacin ursodeoxycholic acid pregnancy safety contraindications
Medical Text Search
Ofloxacin Ornidazole Itraconazole Levocetirizine pregnancy contraindications FDA category
GradeResponse
GradeResponse
Medical Text Search
Zerodol SP aceclofenac serratiopeptidase paracetamol pregnancy NSAID risk
Medical Text Search
norethisterone ethinyl estradiol oral contraceptive pill pregnancy contraindication
Here is a comprehensive breakdown of all six medications and their pregnancy safety/contraindication profiles:
Pregnancy Contraindications & Safety — Drug-by-Drug Analysis
1. Tab Ciprofloxacin + Ursodeoxycholic Acid (UDCA)
Ciprofloxacin
| Parameter | Detail |
|---|---|
| FDA Pregnancy Category | C |
| Pregnancy Safety | ⚠️ Avoid — use only if no safer alternative |
| Risk | Fluoroquinolones bind to developing cartilage and can cause arthropathy in animal models. Although human data show low absolute risk, alternatives are strongly preferred. |
| Breast milk | Excreted in breast milk — avoid during lactation |
| Recommendation | Use safer alternatives (e.g., amoxicillin-clavulanate, cephalosporins) in pregnancy |
Ursodeoxycholic Acid (UDCA)
| Parameter | Detail |
|---|---|
| FDA Pregnancy Category | B |
| Pregnancy Safety | ✅ Relatively safe — commonly used in pregnancy |
| Special use | Drug of choice for Intrahepatic Cholestasis of Pregnancy (ICP/obstetric cholestasis) |
| Risk | No significant teratogenicity demonstrated in human data |
| Recommendation | Generally considered safe in 2nd and 3rd trimester; use with caution in 1st trimester |
Overall for this combination: AVOID due to ciprofloxacin. UDCA alone is safe.
2. Tab Ofloxacin + Ornidazole
Ofloxacin
| Parameter | Detail |
|---|---|
| FDA Pregnancy Category | C |
| Pregnancy Safety | ❌ Contraindicated |
| Risk | Same as all fluoroquinolones — cartilage toxicity, arthropathy in developing fetus; potential CNS effects |
| Recommendation | Avoid throughout pregnancy and lactation |
Ornidazole
| Parameter | Detail |
|---|---|
| FDA Pregnancy Category | Not formally assigned; similar to metronidazole (Category B) |
| Pregnancy Safety | ⚠️ Avoid in 1st trimester; use with caution in 2nd & 3rd trimester |
| Risk | Crosses placenta. Theoretical mutagenicity concerns (based on animal data); limited human safety data compared to metronidazole |
| 1st trimester | Avoid — nitroimidazoles carry theoretical risk of teratogenicity |
| Recommendation | If essential, use after 1st trimester with caution |
Overall for this combination: CONTRAINDICATED — especially due to ofloxacin.
3. Tab Zerodol SP (Aceclofenac + Paracetamol + Serratiopeptidase)
Aceclofenac (NSAID)
| Parameter | Detail |
|---|---|
| FDA Pregnancy Category | C (1st & 2nd trimester), D (3rd trimester) |
| Pregnancy Safety | ❌ Contraindicated in 3rd trimester; avoid in 1st & 2nd if possible |
| Risks | - Premature closure of ductus arteriosus (3rd trimester — serious cardiac defect) |
| - Oligohydramnios (reduced amniotic fluid) | |
| - Delayed labour, fetal renal impairment | |
| - Miscarriage risk if used around conception |
Paracetamol (Acetaminophen)
| Parameter | Detail |
|---|---|
| FDA Pregnancy Category | B |
| Pregnancy Safety | ✅ Safest analgesic in pregnancy at recommended doses |
| Recent concern | Prolonged high-dose use associated with fetal neurodevelopmental effects (observational data) — use lowest effective dose for shortest duration |
Serratiopeptidase
| Parameter | Detail |
|---|---|
| Pregnancy Safety | ⚠️ Insufficient safety data — not recommended |
| Risk | Proteolytic enzyme; theoretical risk to fetal membranes and placental integrity; avoid in pregnancy |
Overall for Zerodol SP: CONTRAINDICATED — primarily due to aceclofenac (NSAID) and serratiopeptidase.
4. Tab Crina NCR (Norethisterone)
Norethisterone (Synthetic Progestogen)
| Parameter | Detail |
|---|---|
| FDA Pregnancy Category | X |
| Pregnancy Safety | ❌ CONTRAINDICATED in pregnancy |
| Risks | - Virilization of female fetus (androgenic progestogen) |
| - Associated with hypospadias in male fetuses | |
| - Risk of VACTERL association (vertebral, cardiac, tracheoesophageal, renal, limb anomalies) with early exposure | |
| Use in pregnancy | Previously used to prevent miscarriage — now largely abandoned due to teratogenic risk |
| Note | If pregnancy is detected while on norethisterone, discontinue immediately and counsel regarding fetal risk |
Overall: ABSOLUTELY CONTRAINDICATED in pregnancy — Category X.
5. Tab Itraconazole
| Parameter | Detail |
|---|---|
| FDA Pregnancy Category | C |
| Pregnancy Safety | ❌ Avoid — not recommended in pregnancy |
| Risks | - Teratogenic at high doses in animal studies (skeletal defects, embryotoxicity) |
| - Human case series do not conclusively show increased teratogenicity, but data are limited | |
| - Structural abnormalities reported with systemic azole use | |
| 1st trimester | Contraindicated for systemic use |
| Preferred alternative | Topical antifungals (clotrimazole, nystatin) for vaginal/cutaneous fungal infections in pregnancy |
| If systemic antifungal essential | Amphotericin B is preferred for severe systemic fungal infections in pregnancy |
Overall: AVOID throughout pregnancy — especially in 1st trimester.
6. Tab Levocetirizine
| Parameter | Detail |
|---|---|
| FDA Pregnancy Category | B |
| Pregnancy Safety | ✅ Relatively safe — one of the preferred antihistamines in pregnancy |
| Evidence | No teratogenicity in animal studies; limited but reassuring human data |
| Preferred antihistamines | Cetirizine and levocetirizine are considered acceptable when antihistamine is needed |
| 1st trimester | Use with caution; avoid if possible in very early pregnancy |
| Recommendation | Chlorpheniramine (Category B) is traditionally the most-used antihistamine in pregnancy in many guidelines; levocetirizine is an acceptable alternative |
Overall: Relatively safe, but avoid unnecessary use especially in 1st trimester.
Summary Table — Pregnancy Safety at a Glance
| Drug | FDA Category | Pregnancy Verdict |
|---|---|---|
| Ciprofloxacin | C | ⚠️ Avoid — alternatives preferred |
| Ursodeoxycholic Acid | B | ✅ Safe (used for ICP in pregnancy) |
| Ofloxacin | C | ❌ Contraindicated |
| Ornidazole | — (B-like) | ⚠️ Avoid 1st trimester |
| Aceclofenac (Zerodol SP) | C/D | ❌ Contraindicated (3rd trimester absolute) |
| Serratiopeptidase | Unclassified | ⚠️ Avoid — insufficient data |
| Norethisterone (Crina NCR) | X | ❌❌ Absolutely contraindicated |
| Itraconazole | C | ❌ Avoid — teratogenic risk |
| Levocetirizine | B | ✅ Relatively safe |
Key Takeaway
Of all the drugs listed, Norethisterone (Crina NCR) carries the most severe contraindication (Category X). Itraconazole, Ofloxacin, Aceclofenac, and Ornidazole should all be avoided or replaced with safer alternatives in any pregnant or potentially pregnant patient. UDCA and Levocetirizine are the safest agents in this list for use during pregnancy.
This is a shared conversation. Sign in to Orris to start your own chat.